Kazazian Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kazazian Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,569	Closed	-$220K	–	60
2019 Q2	$220K	Sell	2,569 -333	-11%	-$28.5K	0.26%	54
2019 Q1	$258K	Sell	2,902 -1,000	-26%	-$92.7K	0.36%	46
2018 Q4	$332K	Sell	3,902 -2,122	-35%	-$202K	0.45%	41
2018 Q3	$584K	Buy	6,024 +2,890	+92%	+$288K	0.55%	43
2018 Q2	$295K	Sell	3,134 -120	-4%	-$10.5K	0.27%	71
2018 Q1	$264K	Hold	3,254	–	–	0.28%	66
2017 Q4	$290K	Buy	+3,254	New	+$283K	0.3%	66
2017 Q3	–	Sell	-3,424	Closed	-$311K	–	71
2017 Q2	$311K	Buy	+3,424	New	+$312K	0.47%	39

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Kazazian Asset Management's BMRN Position: Q3 2019 in Review

Kazazian Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 2,569 shares — an estimated $220K sold.

Kazazian Asset Management first reported a position in BMRN in Q2 2017 and held it in 8 quarters. The position peaked at $584K in Q3 2018. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Kazazian Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Kazazian Asset Management sold 2,569 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $220K.
Kazazian Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2017 and held it in 8 quarters.
Kazazian Asset Management's BioMarin Pharmaceuticals position peaked at $584K in Q3 2018.
436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Kazazian Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.